Johnson & Johnson announced this Monday (8) the acquisition of the biotechnology company Firefly Bio for US$ 1 billion in cash, in a move that reinforces its expansion strategy in the oncology area.
The pharmaceutical company said it expects to complete the transaction later this year, subject to customary closing conditions.
Firefly Bio develops a proprietary platform called Firelink, aimed at treating cancers driven by mutations in the KRAS gene.
Study abroad
Upgrade your career!
This type of genetic alteration is present in several aggressive tumors and, historically, has been considered one of the biggest challenges in oncology research due to the difficulty of developing drugs capable of acting directly on it.
According to Johnson & Johnson, Firefly’s technology uses an approach based on conjugates of antibodies with protein degraders, allowing treatment to be targeted more selectively to tumor cells.
The expectation is to overcome limitations observed in currently available therapies and reduce damage to healthy tissues.
Continues after advertising
The company highlighted that patients with KRAS-related tumors still face limited therapeutic options and, in many cases, survival rates measured in a few months.
The acquisition seeks to accelerate the development of new alternatives for this group of patients, considered one of the priorities of the pharmaceutical industry in oncology.
The agreement reinforces the trend of large pharmaceutical companies resorting to acquisitions of biotechnology companies to expand their innovation pipelines.
In recent years, the cancer segment has concentrated a relevant part of these transactions, as global groups compete for access to promising technologies and new highly complex treatments.
